Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other financing activities (2019 - 2021)

Harmony Biosciences Holdings recorded quarterly Other financing activities of $8.9 million in Q4 2021, up 252.96% quarter-over-quarter from -$5.8 million in Q4 2020, and up 252.96% year-over-year from $2.5 million in Q4 2020.

Harmony Biosciences Holdings' Other financing activities history runs 3 years deep, the most recent figure standing at $8.9 million for Q4 2021.

  • In Q4 2021, Other financing activities rose 252.96% year-over-year to $8.9 million; the TTM figure through Dec 2023 stood at $3.1 million (changed N/A YoY), while the FY2023 annual figure was $3.0 million, changed N/A from the prior year.
  • Other financing activities came in at $8.9 million for Q4 2021 at Harmony Biosciences Holdings, up from -$5.8 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $8.9 million in Q4 2021 to a low of -$5.8 million in Q4 2020.
  • A 3-year average of $2.0 million and a median of $875000.0 in 2019 frame the typical range for Other financing activities.
  • Across the five-year window, Other financing activities tumbled 761.37% in 2020 and soared 252.96% in 2021, its largest moves.
  • Harmony Biosciences Holdings' Other financing activities stood at $875000.0 in 2019, then sank by 761.37% to -$5.8 million in 2020, then jumped by 252.96% to $8.9 million in 2021.
  • According to Business Quant data, Other financing activities over the past three periods registered $8.9 million, -$5.8 million, and $17000.0 for Q4 2021, Q4 2020, and Q3 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Harmony Biosciences Holdings 1.83 Bn 1.19 Bn 170.88 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 8.85 Mn
Dec 31, 2021 8.85 Mn
Dec 31, 2020 -5.79 Mn
Dec 31, 2020 -5.79 Mn
Sep 30, 2020 17,000.00
Sep 30, 2020 17,000.00
Mar 31, 2020 5.80 Mn
Mar 31, 2020 5.80 Mn
Dec 31, 2019 875,000.00
Dec 31, 2019 875,000.00